Evolving Designs for HIV Prevention Trials

There are more biomedical strategies available for HIV prevention than ever before. At the same time, research is continuing. Trials must be able to test new tools and meet ethical standards by providing participants with the best available prevention package.

Special Interview with AVAC’s Micheal Ighodaro

This episode of Px Pulse, Special Interview with AVAC’s Micheal Ighodaro, goes behind the scenes of the new HBO movie, The Legend of the Underground. The film documents the lives of AVACer Micheal Ighodaro and other LGBTQ Nigerians as they confront enormous risks to ‘live out loud’. As the movie unfolds, individual stories of resilience are woven together into a tapestry that portrays a revolution for cultural change in Nigeria.

No Data No More: Manifesto to Align HIV Prevention Research with Trans and Gender Diverse Realities

No Data No More: Manifesto to Align HIV Prevention Research with Trans and Gender Diverse Realities, written and informed by trans and gender-diverse (TGD) activists from Cape Town to Berlin, with support and solidarity from AVAC, offers practical and essential priorities for demonstrable and viable HIV interventions for TGD people.

This manifesto reflects the urgent need for peer-led HIV prevention research with true ownership and acceptability in TGD communities.

Also available: download the Manifesto summary for a snapshot of key recommendations

How can research ethics committees help to strengthen stakeholder engagement in health research in South Africa? An evaluation of REC documents

The authors recommend research ethics committees (RECs) amend their application forms to better ‘trigger’ researchers to thoughtfully plan sound stakeholder engagement. In the longer term, RECs’ documents should be better harmonised internally regarding their stance on stakeholder engagement.

Essential Principles & Practices for GPP Compliance: Engaging stakeholders in biomedical research during the era of COVID-19

This document is a new tool to help guide stakeholder engagement in COVID-19 research. Built from the Good Participatory Practice Guidelines for Biomedical HIV Prevention Trials (GPP), this document responds to needs expressed by both researchers and advocates as the world watched COVID-19 research progress with unprecedented speed and urgency.

Ethical considerations in HIV prevention trials

UNAIDS and the World Health Organization have published this updated guidance on ethical considerations in HIV prevention trials. The new guidance is the result of a year-long process that saw more than 80 experts and members of the public give inputs and is published 21 years after the first edition appeared.

COMPASS

Since 2017, the Coalition to Build Momentum, Power, Strategy and Solidarity has broken new ground in transnational HIV activism that’s grounded in rigorous analysis, fearless tactics and collaboration across geographies. We’re winning commitments and changes that will drive epidemic control. Read on to see what the future of AIDS activism looks like.

Advocates Call for Ethical Research for COVID-19 Solutions

More than 260 organizations and individuals have joined an Advocates Call for Ethical Research for COVID-19 Solutions. Read the letter reiterating the essential role of ethical research, and the need to move forward based on facts and evidence, and help us carry this message forward!

AVAC’s “3D” View of the World: 2019 and beyond

This infographic lays out AVAC’s top-line recommendations from AVAC Report 2019: Now What? The recommendations fall into three categories: deliver — prevention programs whose impact is well-measured and -defined; demonstrate — next-generation engagement for next-generation trials; develop — new targets for the post-2020 world.

Visualizing Multisectoral Prevention: The DREAMS program theory of change

This is PEPFAR’s own visualization of how its AGYW programs can effect change. It’s notable for the definition of a care package that touches on the individual and her community, and for the way it defines a range of outcomes. There isn’t anything comparable for PEPFAR’s Key Population Investment Fund, which is infusing resources into a range of countries. Some of that funding is going for ART; for primary prevention, a theory of change linked to incidence is a must. AVAC is working with allies in KPIF countries to make this demand.

Excerpted from AVAC Report 2019: Now What?